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Background
The adoptive transfer of tumor infiltrating lymphocytes
(TIL) can mediate the regression of metastatic mela-
noma. In addition, the adoptive transfer of lymphocytes
genetically modified to express tumor reactive T cell
receptors (TCRs) can mediate tumor regression. Many
T cells from TIL recognize mutated antigens expressed
only on the autologous patient’s tumors. Therefore, we
attempted to isolate TCRs reactive with unique mutated
antigens so that we might eventually be able to treat
patients with autologous T cells genetically modified to
express those TCRs.
Methods
Mutations in tumors were identified using whole exome
sequencing and/or RNA sequencing. Tandem minigene
(TMG) constructs containing 12-24 minigenes were
synthesized, each encoding the mutated amino acid
flanked by 12 amino acids on both sides. RNAs encoding
the TMGs were in vitro transcribed and electroporated
into autologous dendritic cells (DCs). Recognition of
TMGs by TIL was evaluated on the basis of IFN-g secre-
tion and CD137 expression after overnight coculture
with the electroporated DCs. Subsequently, mutation
reactive T cells were enriched from TIL by sorting for
CD137+ T cells after overnight coculture with the elec-
troporated DCs and were expanded in vitro with anti-CD3
and IL-2. Dominant TCR a and b chain sequences were
identified in the enriched mutation reactive populations,
and retroviruses encoding those TCRs were used to trans-
duce human PBL to determine if they mediated recogni-
tion of the mutated antigen.
Results
Thus far, using these techniques we have isolated muta-
tion reactive TCRs from 6 different patients with meta-
static melanoma as described in the attached table. We
are currently extending these techniques to identify
mutation reactive TCRs for patients with other cancers
including those of the gastrointestinal tract, breast, and
ovaries. We are also developing clinical reagents to treat
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Table 1 Mutation reactive TCRs identified by CD137
upregulation.











3716 Not yet identified at individual gene
level
1
4000 Not yet identified at individual gene
level
Up to 4
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patients with TCRs that recognize unique mutations on
autologous tumor cells.
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